Our aim was to compare the efficacy and safety of two recently developed biosimilars of
pegfilgrastim, a pegylated form of the recombinant human granulocyte‐colony stimulating …

Purpose Pegfilgrastim is a long-acting granulocyte colony-stimulating factor indicated for
prevention of febrile neutropenia in patients receiving myelosuppressive chemotherapy by …

Abstract Pegfilgrastim-jmdb/MYL-1401H (FULPHILA™)[hereafter referred to as pegfilgrastim-
jmdb] is a biosimilar of the reference pegylated recombinant granulocyte colony-stimulating …

Abstract In 1991, the US Food & Drug Administration (FDA) approved rmetHuGCSF for
human use. This recombinant methionyl human granulocyte colony-stimulating factor, or …

Introduction: Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is
indicated for reduction of incidence of febrile neutropenia in patients with non-myeloid …

BACKGROUND: Real-world evidence on the comparative effectiveness of pegfilgrastim
biosimilars compared with the originator product is limited. OBJECTIVE: To compare the risk …

Introduction Cancer patients receiving myelosuppressive chemotherapy are vulnerable to
febrile neutropenia (FN) which contributes to poor treatment outcomes. The use of …

Febrile neutropenia (FN) is a serious complication of chemotherapy, which can cause
significant morbidity and mortality, result in dose delays and reductions and, ultimately …

Chemotherapy is still one of the main tools for treatment of pediatric and adult blood and
solid tumors and is capable of cure some acute leukemia, some advanced lymphomas …

Background Chemotherapy-induced neutropenia is a common result of myelosuppressive
chemotherapy treatment. Infections such as febrile neutropenia (FN) are sensitive to the …